furmonertinib

Phase 3Small molecule

AAllist Pharmaceuticals, Inc.

furmonertinib is one of 288 small molecule programs targeting Lung Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

287

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung AdenocarcinomaRecruiting

Lung Cancer (NSCLC)Not yet recruiting

NSCLCActive, not recruiting

Leptomeningeal MetastasesRecruiting

Combination TherapyRecruiting

Brain MetastasesNot yet recruiting

MetastasisRecruiting

Non-Small Cell Lung CancerRecruiting

Non-Small Cell Lung CarcinomaUnknown status

Lung CancerRecruiting

Lung AdenocarcinomaPhase 2

Recruiting

Lung Cancer (NSCLC)Phase 2

Not yet recruiting

NSCLCPhase 2

Active, not recruiting

Leptomeningeal MetastasesPhase 2

Recruiting

Combination TherapyPhase 2

Recruiting

Brain MetastasesPhase 2

Not yet recruiting

MetastasisPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Non-Small Cell Lung CarcinomaPhase 2

Unknown status

Lung CancerPhase 2

Recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Navelbine

PPierre Fabre Medicament

Phase 3

24 2

furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 3

6 3

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

3 4

Sac-TMT

Merck & Co.

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Osimertinib

NCT06117644

Phase 2Active, not recruiting

NSCLC

NCT05466149

Phase 2Not yet recruiting

Brain Metastases

NCT06319950

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT05364073

Q1 2027

Phase 2Recruiting

Non-Small Cell Lung Carcinoma

NCT06192849

Q2 2027

Phase 2Not yet recruiting

Advanced or Metastatic NSCLC

NCT07193160

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Active, not recruiting·AArriVent BioPharma, Inc.·Phase 3·NCT05607550·398 enrolled

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05445310·114 enrolled

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Active, not recruiting·AArriVent BioPharma, Inc.·Phase 1·NCT05364073·160 enrolled

Show 3 more trials

A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Unknown status·SSun Yat-sen University·Phase 2·NCT04970693·64 enrolled

A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07622186·150 enrolled

Furmonertinib Mesylate Neoadjuvant Treatment of Resectable Stage Ⅱ-ⅢB Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor（EGFR）Sensitive Mutation：a Prospective，Muliticenter，Open Label，Phase Ⅱ Single-arm Study

Recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT05987826·40 enrolled

Lung Adenocarcinoma4 trials

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Unknown status·PPeking University People's Hospital·Phase 1/2·NCT05079022·50 enrolled

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04965831·40 enrolled

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT05503667·96 enrolled

Show 1 more trial

Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

Not yet recruiting·—·Phase 2·NCT06483672·27 enrolled

Locally Advanced or Metastatic NSCLC2 trials

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Unknown status·FFudan University·Phase 2·NCT05255406·62 enrolled

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Recruiting·PPeking Union Medical College Hospital·Phase 3·NCT06674343·144 enrolled

Metastasis2 trials

A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06945705·146 enrolled

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Recruiting·TTang-Du Hospital··NCT06352502·30 enrolled

Combination Therapy2 trials

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05994131·110 enrolled

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting·SSun Yat-sen University·Phase 2·NCT05334277·280 enrolled

16 more indications

Leptomeningeal Metastasis2 trials

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Recruiting·HHenan Cancer Hospital·N/A·NCT06643000·60 enrolled

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Recruiting·JJiangsu Province Nanjing Brain Hospital·Phase 2·NCT06339242·30 enrolled

Non-Small Cell Lung Carcinoma2 trials

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Unknown status·TTongji University·Phase 2·NCT05165355·90 enrolled

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Recruiting·JJuan LI, MD·Phase 2·NCT06192849·20 enrolled

NSCLC2 trials

A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations

Active, not recruiting·AAllist Pharmaceuticals, Inc.·Phase 2·NCT05466149·100 enrolled

A Phase Ib, Randomized, Open-label, Multi-center Study to Evaluate the Preliminary Efficacy and Safety of Furmonertinib Mesilate in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation

Completed·AAllist Pharmaceuticals, Inc.·Phase 1·NCT04858958·90 enrolled

Osimertinib1 trial

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Not yet recruiting·—··NCT06117644·30 enrolled

Leptomeningeal Metastases1 trial

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07304739·30 enrolled

Phase IB1 trial

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Withdrawn·AAllist Pharmaceuticals, Inc.·Phase 1·NCT04958967

Central Nervous System1 trial

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT05379803·40 enrolled

Brain Metastases1 trial

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Not yet recruiting·TTaizhou Hospital·Phase 2·NCT06319950·255 enrolled

First-line Treatment1 trial

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Unknown status·SShanghai Chest Hospital·Phase 2·NCT04895930·40 enrolled

Treatment1 trial

Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

Unknown status·RRuijin Hospital·Phase 2·NCT04982900·138 enrolled

Lung Cancer1 trial

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Recruiting·MMinghui Pharmaceutical (Hangzhou) Ltd·Phase 1/2·NCT07229599·300 enrolled

Advanced or Metastatic NSCLC1 trial

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Not yet recruiting·FFudan University·Phase 2·NCT07193160·45 enrolled

Efficacy and Safety1 trial

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07365410·60 enrolled

Second-line Treatment1 trial

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Recruiting·—·Phase 2·NCT06394674·84 enrolled

Non Small Cell Lung Cancer Metastatic1 trial

A Single-arm, Multicenter, Phase 2 Study of High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Completed·SSun Yat-sen University·Phase 2·NCT06812871·46 enrolled

Lung Cancer (NSCLC)1 trial

A Prospective, Multicenter Study on the Safety and Efficacy of Furmonertinib Combined With Local Chest Radiotherapy in EGFR+ Non-small Cell Lung Adenocarcinoma Patients With Malignant Pleural Effusion

Not yet recruiting·UUnknown Sponsor·Phase 2·NCT07482605·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 35 trial records for furmonertinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — furmonertinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for furmonertinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allist Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAllist Pharmaceuticals, Inc.

furmonertinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

Lung Adenocarcinoma4 trials

Locally Advanced or Metastatic NSCLC2 trials

Metastasis2 trials

Combination Therapy2 trials

Leptomeningeal Metastasis2 trials

Non-Small Cell Lung Carcinoma2 trials

NSCLC2 trials

Osimertinib1 trial

Leptomeningeal Metastases1 trial

Phase IB1 trial

Central Nervous System1 trial

Brain Metastases1 trial

First-line Treatment1 trial

Treatment1 trial

Lung Cancer1 trial

Advanced or Metastatic NSCLC1 trial

Efficacy and Safety1 trial

Second-line Treatment1 trial

Non Small Cell Lung Cancer Metastatic1 trial

Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News